169 related articles for article (PubMed ID: 21069551)
1. Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.
Itoh M; Goto A; Wakasugi H; Yoshida Y; Matsunaga Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Arimura Y; Shinomura Y
Int J Clin Oncol; 2011 Aug; 16(4):428-34. PubMed ID: 21069551
[TBL] [Abstract][Full Text] [Related]
2. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
[TBL] [Abstract][Full Text] [Related]
3. Anorectal Melanoma - a Histopathological Case Report and a Review of the Literature.
Kobakova I; Stoyanov G; Popov H; Spasova-Nyagulova S; Stefanova N; Stoev L; Yanulova N
Folia Med (Plovdiv); 2018 Dec; 60(4):641-646. PubMed ID: 31188769
[TBL] [Abstract][Full Text] [Related]
4. KIT genetic alterations in anorectal melanomas.
Santi R; Simi L; Fucci R; Paglierani M; Pepi M; Pinzani P; Merelli B; Santucci M; Botti G; Urso C; Massi D
J Clin Pathol; 2015 Feb; 68(2):130-4. PubMed ID: 25398993
[TBL] [Abstract][Full Text] [Related]
5. c-kit gene mutation and CD117 expression in human anorectal melanomas.
Ni S; Huang D; Chen X; Huang J; Kong Y; Xu Y; Du X; Sheng W
Hum Pathol; 2012 Jun; 43(6):801-7. PubMed ID: 22154054
[TBL] [Abstract][Full Text] [Related]
6. Identification of recurrent mutational events in anorectal melanoma.
Yang HM; Hsiao SJ; Schaeffer DF; Lai C; Remotti HE; Horst D; Mansukhani MM; Horst BA
Mod Pathol; 2017 Feb; 30(2):286-296. PubMed ID: 27739435
[TBL] [Abstract][Full Text] [Related]
7. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
8. Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
Schoenewolf NL; Urosevic-Maiwald M; Dummer R
Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997
[TBL] [Abstract][Full Text] [Related]
9. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
Schaefer T; Satzger I; Gutzmer R
Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
[TBL] [Abstract][Full Text] [Related]
10. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Meng D; Carvajal RD
Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
[TBL] [Abstract][Full Text] [Related]
11. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
12. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
13. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic implications of KIT in melanoma.
Postow MA; Carvajal RD
Cancer J; 2012; 18(2):137-41. PubMed ID: 22453014
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
[TBL] [Abstract][Full Text] [Related]
16. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
17. C-kit-mutated melanomas: the Chinese experience.
Si L; Guo J
Curr Opin Oncol; 2013 Mar; 25(2):160-5. PubMed ID: 23299198
[TBL] [Abstract][Full Text] [Related]
18. Primary anorectal malignant melanoma: an uncommon anorectal pathology.
Juanmartiñena Fernández JF; Fernández-Urien I; Córdoba A
Rev Esp Enferm Dig; 2016 Sep; 108(9):604-5. PubMed ID: 27056438
[TBL] [Abstract][Full Text] [Related]
19. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
20. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Cho J; Kim SY; Kim YJ; Sim MH; Kim ST; Kim NKD; Kim K; Park W; Kim JH; Jang KT; Lee J
Clin Transl Oncol; 2017 Oct; 19(10):1247-1252. PubMed ID: 28421416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
